Patterns of interventions for central venous catheter-associated deep vein thrombosis and outcomes in cancer patients.

IF 1 4区医学 Q4 ONCOLOGY

Journal of Oncology Pharmacy Practice Pub Date : 2025-01-01 Epub Date: 2024-01-02 DOI:10.1177/10781552231219995

Dat Ngo, Jason Chen, Chris Nguyen, Kathy Choi, Vinod Pullarkat

{"title":"Patterns of interventions for central venous catheter-associated deep vein thrombosis and outcomes in cancer patients.","authors":"Dat Ngo, Jason Chen, Chris Nguyen, Kathy Choi, Vinod Pullarkat","doi":"10.1177/10781552231219995","DOIUrl":null,"url":null,"abstract":"Purpose: This letter evaluated the impact of different management strategies, specifically the presence or absence of therapeutic anticoagulation, on clinical outcomes for central venous catheter (CVC)-associated deep vein thrombosis (DVT) in cancer patients.Methods: One-hundred ninety-eight adult cancer patients with a confirmed CVC-associated DVT diagnosis from February 2013 and February 2021 were included.Results: Incidence of symptomatic recurrent venous thromboembolism (VTE) was similar between patients who received therapeutic anticoagulation and those who did not (14% vs 16%, p = 0.807). In addition, therapeutic anticoagulation did not significantly alter the incidence of grade 3 and above bleeding events despite most patients having hematologic malignancies (9% vs 8%, p = 0.826).Conclusion and relevance: Therapeutic anticoagulation was not associated with a reduction in the incidence of recurrent VTE or increase the incidence of bleeding in adult cancer patients following a CVC-associated DVT diagnosis.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"12-16"},"PeriodicalIF":1.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552231219995","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/2 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This letter evaluated the impact of different management strategies, specifically the presence or absence of therapeutic anticoagulation, on clinical outcomes for central venous catheter (CVC)-associated deep vein thrombosis (DVT) in cancer patients.

Methods: One-hundred ninety-eight adult cancer patients with a confirmed CVC-associated DVT diagnosis from February 2013 and February 2021 were included.

Results: Incidence of symptomatic recurrent venous thromboembolism (VTE) was similar between patients who received therapeutic anticoagulation and those who did not (14% vs 16%, p = 0.807). In addition, therapeutic anticoagulation did not significantly alter the incidence of grade 3 and above bleeding events despite most patients having hematologic malignancies (9% vs 8%, p = 0.826).

Conclusion and relevance: Therapeutic anticoagulation was not associated with a reduction in the incidence of recurrent VTE or increase the incidence of bleeding in adult cancer patients following a CVC-associated DVT diagnosis.

查看原文本刊更多论文

癌症患者中心静脉导管相关性深静脉血栓的干预模式和结果。

目的：这封信评估了不同管理策略，特别是有无治疗性抗凝对癌症患者中心静脉导管（CVC）相关性深静脉血栓（DVT）临床结局的影响：方法：纳入2013年2月至2021年2月期间确诊为CVC相关性深静脉血栓的198名成年癌症患者：结果：接受治疗性抗凝与未接受治疗性抗凝的患者症状性复发性静脉血栓栓塞症（VTE）发生率相似（14% vs 16%，P = 0.807）。此外，尽管大多数患者患有血液系统恶性肿瘤（9% vs 8%，p = 0.826），但治疗性抗凝并未显著改变3级及以上出血事件的发生率：结论及相关性：治疗性抗凝与降低复发性 VTE 发生率或增加 CVC 相关深静脉血栓诊断后成年癌症患者的出血发生率无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oncology Pharmacy Practice Medicine-Oncology

CiteScore

2.70

自引率

7.70%

发文量

276

期刊介绍： Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...